Oramed's poster has been assigned presentation number PS 093 New
Treatments and is available for viewing throughout the conference. Oramed's
Chief Scientific Officer, Dr.
"The fact that Oramed has been selected to present research at the EASD
Conference underscores the importance of our work developing an oral insulin
capsule," said
For more information about the EASD and the upcoming conference, please visit http://www.easd.org.
About Oramed Pharmaceuticals
Oramed Pharmaceuticals is a technology pioneer in the field of oral
delivery solutions for drugs and vaccines presently delivered via injection.
Oramed is seeking to revolutionize the treatment of diabetes through its
patented flagship product, an orally ingestible insulin capsule currently in
phase 2 clinical trials. Established in 2006, Oramed's technology is based on
over 25 years of research by top research scientists at
For more information, please visit http://www.oramed.com
Forward-looking statements
Some of the statements contained in this press release are forward-looking statements which involve known and unknown risks, uncertainties and other factors which may cause the actual results, performance or achievements of the company, or industry results, to be materially different from any future results, performance or achievements expressed or implied by such forward looking statements, including the risks and uncertainties related to the progress, timing, cost, and results of clinical trials and product development programs; difficulties or delays in obtaining regulatory approval for our product candidates; competition from other pharmaceutical or biotechnology companies; and the company's ability to obtain additional funding required to conduct its research, development and commercialization activities. Please refer to the company's filings with the Securities and Exchange Commission for a comprehensive list of risk factors that could cause actual results, performance or achievements of the company to differ materially from those expressed or implied in such forward looking statements. The company undertakes no obligation to update or revise any forward-looking statements.
Company and Investor Relation Contacts: Oramed Pharmaceuticals Eric Rosenberg Cell: +972-54-566-7713 Office: +972-2-566-0001 Email: eric@oramed.com Media Contacts: Ruder Finn Israel for Oramed Matthew Krieger Cell: +972-54-467-6950 Office: +972-2-589-2003 Email: matthew@oramed.com
SOURCE Oramed Pharmaceuticals Inc.